Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study

Fig. 2

Metabolic parameters and renal function. Urinary glucose excretion (a), 24 h urinary volume (b), eGFR (c), and plasma cystatin C levels (d) in patients with type 2 diabetes treated with empagliflozin (n = 20; black line) or placebo (n = 22; blue dotted line). Data are shown as mean ± standard error at baseline, after 1 day, 3 days, and 3 months. p-values are calculated from Wald tests for the intervention effect at each visit

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840